Matinas BioPharma Holdings (MTNB) Shares Outstanding (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Shares Outstanding (Entity) of $6.4 million for Q1 2026, up 25.93% year-over-year from $5.1 million in Q1 2025, and little changed quarter-over-quarter from $6.4 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Shares Outstanding (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Shares Outstanding (Entity) for 14 consecutive years, with $6.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 25.93% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (up 25.93% YoY), while the FY2025 annual figure was $6.4 million, up 25.93% from the prior year.
- Shares Outstanding (Entity) steadied at $6.4 million in Q1 2026 per MTNB's latest filing, from $6.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $6.4 million in Q4 2025 and bottomed at $4.3 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $4.9 million across 5 years, with a median of $4.3 million in 2024.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) changed 0.0% — and 2025, when it gained 25.93%.
- Matinas BioPharma Holdings' Shares Outstanding (Entity) stood at $4.3 million in 2022, then changed by 0.0% to $4.3 million in 2023, then grew by 17.07% to $5.1 million in 2024, then increased by 25.93% to $6.4 million in 2025, then changed by 0.0% to $6.4 million in 2026.
- Business Quant data shows MTNB's Shares Outstanding (Entity) at $6.4 million in Q1 2026, $6.4 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | 6.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.41 Mn |
| Mar 31, 2026 | 6.41 Mn |
| Dec 31, 2025 | 5.47 Mn |
| Sep 30, 2025 | 5.44 Mn |
| Jun 30, 2025 | 5.09 Mn |
| Mar 31, 2025 | 5.09 Mn |
| Dec 31, 2024 | 4.87 Mn |
| Sep 30, 2024 | 5.04 Mn |
| Jun 30, 2024 | 4.99 Mn |
| Mar 31, 2024 | 4.35 Mn |
| Dec 31, 2023 | 4.35 Mn |
| Sep 30, 2023 | 4.35 Mn |
| Jun 30, 2023 | 4.35 Mn |
| Mar 31, 2023 | 4.35 Mn |
| Dec 31, 2022 | 4.34 Mn |
| Sep 30, 2022 | 4.34 Mn |
| Jun 30, 2022 | 4.34 Mn |
| Mar 31, 2022 | 4.33 Mn |
| Dec 31, 2021 | 4.20 Mn |
| Sep 30, 2021 | 4.30 Mn |